Timeliness of infant vaccination and factors related with delay in Flanders, Belgium

Highlights • One third of infants in Flanders receive MMR1 vaccine delayed according to the recommended schedule. • Although 38% of infants receive DTP1 vaccine in time, 92% of DTP3 doses are administered with delay. • An improvement in timely vaccination was achieved over the last decade. • Determi...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Vaccine 2014-01, Vol.32 (2), p.284-289
Hauptverfasser:	Lernout, Tinne, Theeten, Heidi, Hens, Niel, Braeckman, Tessa, Roelants, Mathieu, Hoppenbrouwers, Karel, Van Damme, Pierre
Format:	Artikel
Sprache:	eng
Schlagworte:	Age Allergy and Immunology Applied microbiology Belgium Biological and medical sciences Clinics Confidence intervals Cross-Sectional Studies Diphtheria-Tetanus-Pertussis Vaccine - administration & dosage Families & family life Family income Family physicians Flanders Fundamental and applied biological sciences. Psychology Humans Immunization Schedule Infant Infant vaccination Infants Infectious diseases Measles Measles-Mumps-Rubella Vaccine - administration & dosage Medical research Microbiology Patient Compliance - statistics & numerical data Population Surveillance Public health Regression analysis Risk Factors Studies Survival analysis Time Factors Timeliness Vaccination - trends Vaccines Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects) Whooping cough
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Highlights • One third of infants in Flanders receive MMR1 vaccine delayed according to the recommended schedule. • Although 38% of infants receive DTP1 vaccine in time, 92% of DTP3 doses are administered with delay. • An improvement in timely vaccination was achieved over the last decade. • Determining factors for remaining delay are the main vaccinator, mother's origin, ranking of the child and income.
ISSN:	0264-410X 1873-2518
DOI:	10.1016/j.vaccine.2013.10.084